It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.

 

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Wordpress Table Plugin

 

The Sustainable Nutrition Group (ASX:TSN) was the biggest winner, up 24%.

The company recently announced it had partnered with Australian Plant Proteins to develop hemp concentrate and isolates, which would allow TSN to enter the $10.8 billion global plant-based ingredients market with limited capex requirements.

Commercialisation is expected to commence in Q4 FY2022 initially in the Australian and New Zealand markets.

Rhinomed (ASX:RNO) was up 11%, with chairman Ron Dewhurst telling shareholders at the AGM that the sales pipeline for the Rhinoswab looks strong into FY22.

“The product we have developed and have regulatory approval from the FDA in the US, and the TGA in Australia, has now been launched in the market and received initial orders from both the New South Wales and Victorian Government and further, has an identifiable pipeline of opportunities, both domestic and international,” he said.

“The early traction we have received makes us very optimistic about the relevance that the Rhinoswab will have for the company.”

Diagnostics tech company, Proteomics (ASX:PIQ) was up 11%.

The company signed off a two-year distribution deal with Apacor to bring its PromarkerD test for diabetic kidney disease to patients in England, Scotland and Wales.

And Volpara Health (ASX:VHT) was also up 11%.

The company’s FY22 half-year revenues increased significantly from NZ$19.9m in the prior corresponding period (pcp) to NZ$29 million.

Healthcare and life sciences expert Scott Power told Stockhead’s Eddy Sunarto that revenue guidance of NZ$25 million in FY 2022 is conservative.

 

Who flatlined?

Flat was PYC Therapeutics (ASX:PYC).

The company recently completed a key translational milestone for its RNA platform, by determining safe and well-tolerated doses of its co-lead drug candidate, VP-001, in monkeys.

The results are a key step towards toxicity studies scheduled for Q1 2022, that will then support the initiation of a first study in humans.

The human study is set to be the first therapy for patients with Retinitis Pigmentosa type 11 and will address the underlying cause of the disease.

 

Who’s the biggest loser?

The biggest loser was Singular Health (ASX:SHG) which dropped 28%.

The company has ventured out of medical markets by forming GeoVR Pty Ltd, a 50/50 joint venture (JV) with TerraCentric with the objective of commercialising the GeoVR technology.

GeoVR allows for mineral exploration and production data to be visualised in a fully interactive 3D environment.

Singular says the JV allows it to focus on the medical solutions sector, while branching out for diversified revenue sources.

And Invion (ASX:IVX) was down 26%.

The company has entered into conditional agreements with RMW Cho Group to co-develop Photosoft technology for cancer and related diseases (indications) with Invion to gain exclusive distribution rights to the tech in Asia Pacific for the indications.

Invion has also launched a $12 million placement and $3 million share purchase plan at $2.20 per share.

Featured Companies

You might be interested in